TRANSFORMING HEALTH MANAGEMENT THROUGH MEANINGFUL DIAGNOSTICS Diasorin is a global leader in specialty testing, advancing infectious disease diagnostics with innovative, high-quality molecular and immunodiagnostic solutions. For over 50 years, Diasorin has delivered trusted results that empower clinicians and laboratories worldwide to optimize patient outcomes. With more than 40 first-to-market tests, Diasorin continues to set the standard for diagnostic innovation and reliability. The LIAISON PLEX® Respiratory Flex Assay, run on our LIAISON PLEX® System, is driven by Flex™ Testing, which enables you to report targeted custom panels selected from a larger list of 19 viruses and bacteria. This customizable approach helps reduce unnecessary testing, ultimately saving on costs while allowing you to address the specific needs of your patient population and seasonal trends. Our newly launched LIAISON PLEX® Bloodstream Infection (BSI) portfolio aids in the fight against sepsis by detecting 48 key bacterial and yeast pathogens, along with 12 crucial antimicrobial resistance genes associated with bloodstream infections and sepsis. The LIAISON PLEX® BSI portfolio comprises the LIAISON PLEX® Gram-Positive (BCP) Assay, LIAISON PLEX® Gram-Negative (BCN) Assay, and LIAISON PLEX® Yeast Blood Culture (BCY) Assay, and supports timely, informed clinical decisions, aiding in the optimization of patient management while reinforcing antimicrobial stewardship. Additionally, our Simplexa® C. auris Direct is a real-time PCR assay and part of the expanding assay portfolio performed on the LIAISON® MDX instrument. Intended for patients suspected of Candida auris colonization, Simplexa® C. auris Direct is the only FDA authorized test supporting prevention and control efforts in healthcare settings, addressing the critical gap in the molecular detection of C. auris colonization. Beyond molecular solutions, Diasorin offers one of the broadest immunodiagnostic portfolios in infectious disease testing, consolidated on the fully automated LIAISON® family of analyzers. With menu breadth covering routine to highly specialized assays, Diasorin enables laboratories to streamline workflows, close diagnostic gaps, and deliver high-impact results with confidence. From routine screening to complex diagnostic challenges—especially amid rising outbreaks, emerging threats, and declining vaccination rates—Diasorin provides the accuracy, efficiency, and reliability healthcare professionals can depend on for the right test, every time.
DCN Dx
DCN Dx, based in Carlsbad, California, is a global leader in IVD CDMO and CRO services. Our multidisciplinary team specializes in creating tailored assay systems, consumables, and instruments for point-of-use applications, with a particular expertise in lateral flow assays. Our personalized approach to IVD product development has supported more than 560 programs from over 260 clients. We can oversee every stage from concept to assay development and platform integration, through clinical trials to manufacturing or only handle the aspects you request. In addition to lateral flow assays, our clinical research expertise extends to a wide range of IVD devices, all with a focus on innovation, usability, and performance. With a commitment to quality, customer satisfaction, and industry-leading expertise, DCN Dx is setting the benchmark for excellence in IVD services. To learn more about how we can support your diagnostic needs, visit dcndx.com.
Bruker
Bruker’s MALDI Biotyper®, the market-leading MALDI-TOF for microbial identification, revolutionized microbiology by providing an identification for over 4000 species in less than 10 minutes starting from culture. Another Bruker innovation, the IR Biotyper®, provides rapid and cost-effective microorganism strain typing using infrared spectroscopy technology to further support proactive infection control. ELITechGroup MDx — a Bruker Company offers a complete portfolio of molecular diagnostics products, including infectious disease reagents and sample-to-result instruments. | Bruker is a performance leader in life science and analytical systems. For over 50 years, Bruker has been driven by a single idea: to provide the best technological solution for each analytical task. Our trusted solutions encompass a wide number of analytical techniques including Mass Spectrometry, Optical and X-Ray Spectroscopy. These market and technology leading products are driving and facilitating success in the food industry. | Bruker is a pioneering scientific solutions provider, advancing the standards in high-performance analytical instruments. We specialize in FT-NIR (Fourier Transform Near-Infrared) spectroscopy for feed and ingredient analysis. Our solutions are designed to help labs improve the quality of their animal feed by providing accurate, real-time data on nutrient content. We use advanced FT-NIR technology to perform comprehensive analysis on a wide range of feeds and raw materials, identifying key nutritional metrics such as protein, fat, moisture, fiber, ash, amino acids, and more. The results from our sophisticated spectroscopy technology enable labs to adjust their feed compositions for optimal animal health and productivity. | Bruker offers advanced solutions to reliably support geologists and mining prospectors on locating and analyzing deposits anytime and anywhere. So it is no wonder that Bruker’s instruments can be found at an altitude of 4,000 meters or in baking hot deserts – reliably delivering high end analysis quickly and on-site. | The performance of any battery, whether in terms of its capacity, lifetime or energy density, is ultimately down to the intrinsic properties of the materials that comprise its anode, cathode, electrolyte and SEI. Bruker has developed a comprehensive suite of characterization techniques to enable scientist to understand and optimize the physical and chemical properties, performance and stability of all battery components and the fully assembled battery cells. | Discover what you can achieve in battery research and manufacturing with a range of advanced technologies. From investigating solutes and electrodes to monitoring battery cell behavior and conducting in situ research on energy storage materials, Bruker scientists will share a wealth of knowledge with you.
bioMerieux Inc.
A world leader in the field of in vitro diagnostics, bioMérieux provides diagnostic solutions (systems, reagents, software) that determine the source of disease to improve patient health. Our products are used for diagnosing infectious diseases. Fast and actionable diagnostics are essential in fighting significant issues like antibiotic resistance and sepsis. | For over 60 years, bioMérieux has pioneered in vitro diagnostics with an unrelenting commitment to improving public health worldwide. With expertise in microbiology and access to cutting-edge science, we help you achieve your food safety and quality goals so you can protect your brand and your bottom line. As your trusted partner in Augmented Diagnostics, we’re harnessing the power of complex data to provide tangible microbiology solutions for our customers. Our experts help you go beyond the test, creating comprehensive and customized plans for minimizing financial and safety risk at every level of your organization. Learn more at: https://www.biomerieux.com/us/en.
Associates of Cape Cod, Inc.
Associates of Cape Cod, Inc., manufactures Fungitell® and the recently released single patient sample format, Fungitell STAT® Assay. The Fungitell product line is the Gold Standard in Rapid Screening for Invasive Fungal Infection (IFI) and is the first and only FDA-cleared & CE marked rapid in vitro diagnostic screening test for IFI (including Candida, Aspergillus & Pneumocystis) that detects (1→3)-ß-D-Glucan in serum. | Associates of Cape Cod, Inc., manufactures Fungitell® and the single patient sample format, Fungitell STAT® Assay. The Fungitell product line is the Gold Standard in Rapid Screening for Invasive Fungal Infection (IFI) and is the first and only FDA-cleared & CE marked rapid in vitro diagnostic screening test for IFI (including Candida, Aspergillus & Pneumocystis) that detects (1→3)-ß-D-Glucan in serum.